Kraig Biocraft Laboratories Announces That Raymond Kutsunai Has Joined Its Business Advisory Board
November 22 2010 - 11:08AM
Marketwired
Kraig Biocraft Laboratories, Inc. (PINKSHEETS: KBLB) announced
today that Raymond Kutsunai, the former general manager of
SmithKline & French Laboratories, Japan, has joined the
Company's Board of Advisors.
Mr. Kutsunai was a central figure in SmithKline & French
Laboratories operations and spectacular growth in Japan. Kutsunai
is the second former major executive from SmithKline to join Kraig
Biocraft Laboratories' advisory board. Earlier this month
SmithKline Beecham's celebrated former CEO and Chairman Henry Wendt
joined the Company's Board of Advisors. SmithKline Beecham, which
became Glaxo SmithKline, is one of the world's largest and most
successful corporations.
"Kraig Biocraft Laboratories is privileged to be able to attract
this extraordinary level of talent," said the Company's founder and
CEO Kim K. Thompson. "We are particularly excited about bringing
Mr. Kutsunai onto the team. He rightfully deserves his stellar
reputation in Japan for accomplishment and integrity. In addition
to his extensive business experience and leadership Mr. Kutsunai
also has extensive contacts in Japan which may prove to be
invaluable as our Company grows. His proven record for
orchestrating and managing explosive growth is exactly what we need
as we move to commercialize our technologies."
Kraig Biocraft Laboratories is a fully reporting biotechnology
company, which recently achieved a series of scientific
breakthroughs with implications for the global textile
industry.
To learn more about Kraig Biocraft Laboratories and its recent
commercial and scientific breakthroughs please visit
www.KraigLabs.com. The website hosts several short videos
describing the Company's recent commercial and technological
breakthroughs and outlines the commercial potential that has
garnered attention of many scientific and trade journals.
Statements in this press release about the company's future and
expectations other than historical facts are "forward-looking
statements." These statements are made on the basis of management's
current views and assumptions. As a result, there can be no
assurance that management's expectations will necessarily come to
pass. These forward-looking statements generally can be identified
by phrases such as "believes," "plans," "expects," "anticipates,"
"foresees," "hopes," "develops," "researching," "research,"
"potential," "implications," "could" or other words or phrases of
similar import. Similarly, statements in this release that describe
the Company's business strategy, outlook, objectives, plans,
intentions or goals should all be considered forward-looking
statements. All such forward-looking statements are subject to
certain risks and uncertainties that could cause actual results to
differ materially from those in forward-looking statements.
Management cautions that its ability to further its research, and
create commercially-viable products may be affected by the
competitive environment, the Company's financial condition and its
ability to raise sufficient capital to meet the financial
obligations of its business plan and to fund its continuing
operations.
Contact: Ben Hansel (720) 288-8495
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From May 2024 to Jun 2024
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From Jun 2023 to Jun 2024